Curated News
By: NewsRamp Editorial Staff
September 15, 2026
NanoViricides to Launch Phase II Ebola Trial of Oral NV-387 in DRC
TLDR
- NanoViricides starts Phase II Ebola trial for NV-387 oral gummies, potentially first oral broad-spectrum antiviral against Ebola.
- The adaptive Phase IIA/IIB trial evaluates NV-387 oral gummies safety then efficacy in Ebola patients in DRC.
- Oral NV-387 could offer practical, accessible Ebola treatment in resource-limited areas, improving outbreak response.
- NanoViricides' NV-387 mimics host features to block Ebola, making viral escape less likely than antibody treatments.
Impact - Why it Matters
The launch of this Phase II trial represents a critical step in the fight against Ebola, particularly the Bundibugyo strain, which is currently causing an expanding outbreak in the DRC. If successful, NV-387 Oral Gummies could provide a much-needed oral treatment option that is easier to administer in resource-limited settings than current infusion-based therapies. This could significantly improve patient access and outbreak response. Moreover, the broad-spectrum nature of NV-387 suggests potential against other viral threats, including RSV, COVID, and influenza. Investors and public health officials alike should watch this trial closely, as positive results could validate NanoViricides' nanoviricide platform and open doors to multiple antiviral applications.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has announced that its Phase II clinical trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus and other Ebola viruses will begin next week at an Ebola Treatment Center in the Ituri province of the Democratic Republic of Congo. The adaptive Phase IIA/IIB trial will first evaluate safety and dosing before moving to a randomized, controlled, open-label efficacy evaluation. Prof. Patrick de Marie Chimusa Katoto serves as principal investigator, with Om Sai Clinical Research leading the study. The company expects to dose its first Ebola patient next week, assuming no outbreak-related delays.
NV-387 is an orally administered broad-spectrum antiviral designed to mimic host-side features that Ebola viruses require for infection. NanoViricides believes this approach could make viral escape less likely than with antibody-based treatments. The oral formulation may also offer practical advantages over infusion-based therapies, especially in resource-constrained areas. The company cautioned that clinical trial data will determine whether NV-387 is effective against Ebola, and noted that the trial is launching amid a rapidly expanding Bundibugyo Ebolavirus outbreak in the DRC. For the full press release, visit https://ibn.fm/21nLx.
NanoViricides is a clinical-stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. Another advanced candidate, NV-HHV-1, targets Shingles. The company’s nanoviricide™ technology is based on intellectual property from TheraCour Pharma, Inc., and NanoViricides holds a worldwide exclusive perpetual license for several human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex, Varicella-Zoster, Influenza, Dengue, Japanese Encephalitis, West Nile, Ebola/Marburg, and certain Coronaviruses. The company also develops NV-CoV-2 and NV-CoV-2-R for COVID-19. For more information, visit www.nanoviricides.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides to Launch Phase II Ebola Trial of Oral NV-387 in DRC
